Investigating soluble CD40 ligand as a prognostic factor among acute coronary syndromes patients: A multi-center prospective case-control study
Reham Nofal,Nafiza Martini,Majd Hanna,Imad-Addin Almasri,Ahmad Rasheed Alsaadi,Tahani Ali
DOI: https://doi.org/10.1097/md.0000000000039891
IF: 1.6
2024-09-29
Medicine
Abstract:Soluble CD40 ligand (sCD40L) is a protein that plays a crucial role in the inflammatory response associated with the development and progression of acute coronary syndrome (ACS). [ 1 ] ACS is a group of conditions that includes unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). [ 1 ] Soluble CD40L is generated through the cleavage of CD40L, which is a transmembrane glycoprotein belonging to the tumor necrosis factor superfamily that is expressed on activated T cells, platelets, endothelial cells, smooth muscle cells, and macrophages. The release of sCD40L into the circulation has been shown to be associated with the activation of the immune system and the development of atherosclerosis, which is a major risk factor for ACS. [ 2 ] Recent studies have suggested that sCD40L may be a useful prognostic factor for ACS, patients with high levels of sCD40L had a higher risk of death, myocardial infarction, and revascularization compared to those with low levels of sCD40L. [ 1 ] However, data from literature are conflicting, and the prognostic value of sCD40L in patients with ACS remains uncertain. Therefore, in the present study, we aimed to provide further evidence on the potential role of sCD40L as a prognostic factor in clinical practice among ACS patients.
medicine, general & internal